| 000 | 01858 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515233345.0 | ||
| 264 | 0 | _c20100910 | |
| 008 | 201009s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6605819 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarrido-Laguna, I | |
| 245 | 0 | 0 |
_aIntegrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cAug 2010 |
||
| 300 |
_a649-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntracellular Signaling Peptides and Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aSirolimus _xtherapeutic use |
| 650 | 0 | 4 | _aTOR Serine-Threonine Kinases |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aTan, A C | |
| 700 | 1 | _aUson, M | |
| 700 | 1 | _aAngenendt, M | |
| 700 | 1 | _aMa, W W | |
| 700 | 1 | _aVillaroel, M C | |
| 700 | 1 | _aZhao, M | |
| 700 | 1 | _aRajeshkumar, N V | |
| 700 | 1 | _aJimeno, A | |
| 700 | 1 | _aDonehower, R | |
| 700 | 1 | _aIacobuzio-Donahue, C | |
| 700 | 1 | _aBarrett, M | |
| 700 | 1 | _aRudek, M A | |
| 700 | 1 | _aRubio-Viqueira, B | |
| 700 | 1 | _aLaheru, D | |
| 700 | 1 | _aHidalgo, M | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 103 _gno. 5 _gp. 649-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6605819 _zAvailable from publisher's website |
| 999 |
_c20004522 _d20004522 |
||